Poster Presentations

Board no.

Poster title

1

IMMUNE CHECKPOINTS IN PRIMARY IMMUNE THROMBOCYTOPAENIA (ITP): FROM BENCH TO BEDSIDE

Sasfia Candrianita1,2; Anwar A. Sayed1,3; Rudi Supriyadi4; Nichola Cooper1,5

1Centre for Haematology, Imperial College London, London, UK, 2Immunology Study Centre, Faculty of Medicine, Universitas Padjadjaran,
Bandung, Indonesia
, 3Department of Medical Microbiology and Immunology, Taibah University, Medina, Saudi Arabia, 4Department of Internal Medicine, Dr. Hasan Sadikin General Hospital / Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, 5Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

2

Systematic review of tyrosine kinase inhibitors (TKI) for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance to at least one prior TKI

Eva Susanne Dietrich1; Andrea Rathmann-Schmitz2; Veronika Schneck2; Christina Keksel2; Oliver Schönborn-Kellenberger3

1Institute for Evidence-based Positioning in Healthcare, Germany, 2MEDAHCON GmbH, 3Cogitars GmbH

3

COMPARATIVE ANALYSIS OF ENOXAPARIN VERSUS RIVAROXABAN IN THE TREATMENT OF CANCER ASSOCIATED
VENOTHROMBOEMBOLISM: EXPERIENCE FROM A TERTIARY CARE CANCER CENTER

Anadil Faqah, Hassan Sheikh; Muhammad Abubakar; Fatima Tayyaab; Sahrish Khawaja

Shaukat Khanum Memorial Cancer Hospital & Research Center, Pakistan

4

EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL
OBSTRUCTION SYNDROME FOLLOWING HAEMATOPOIETIC CELL TRANSPLANTATION: INTERIM RESULTS FROM THE DEFIFRANCE STUDY

Anne Huynh1; Myriam Labopin2; Ibrahim Yakoub-Agha3; Didier Blaise4; Régis Peffault de Latour5; Virginie Bouvatier6; Déborah Gutierrez6; Jean-Hughes Dalle7; Mohamad Mohty2

1Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, 2Hôpital Saint-Antoine, Paris, 3Hôpital Claude Huriez, Lille, 4Institut Paoli Calmettes, Marseille, 5Hôpital Saint-Louis, Paris, 6Jazz Pharmaceuticals, Lyon, 7Hôpital Robert-Debré, Paris, France

5

CNS INVOLVEMENT AT PRESENTATION IN AML: A RETROSPECTIVE CASE SERIES

Adtil Jain; Nivedita Dhingra; Tulika Seth; Manoranjan Mahapatra

Clinical Hematology, AIIMS, New Delhi, Delhi, India

6

THIRD PARTY MESENCHYMAL STROMAL CELLS FOR THERAPY OF ACUTE GRAFT-VERSUS-HOST DISEASE A SINGLE CENTER
EXPERIENCE

Eva Mischak-Weissinger

Hannover Medical School, Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Niedersachsen, Germany

7

Anti-Leukemic Effects of Simvastatin on NRASG12D Mutant Acute Myeloid Leukemia Cells

Silvia Park1; Jiryeon Jang2,3

1Department of Internal Medicine, Seoul St. Mary’s Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 2Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Korea;
, 3Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital,
Pusan National University School of Medicine, Yangsan, Korea

8

Comparison of post-transplant outcome by conditioning intensity in patients with minimal residual disease negative acute myeloid leukemia (MRDneg AML)

Silvia Park1; Byung Sik Cho2,3; Hee-Je Kim2,3

1Department of Internal Medicine, Seoul St. Mary’s Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 2Department of Internal Medicine, Seoul St. Mary’s Hematology Hospital, College of Medicine, The Catholic University of Korea,
Seoul, Republic of Korea.
, 3Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea

9

HALVING TIME OF BCR-ABL1 IN CHRONIC MYELOID LEUKEMIA, IS IT BETTER THAN A 90 DAY VALUE? A MULTICENTRE
STUDY FROM INDIA

Krishnakumar Rathnam1; Arun Seshachalam2; Shashidhar Karpurmath3; Manjunath Nandennavar3; Kalaiselvi Selvaraj4; Neelesh Reddy5; Sringeri Roopa5; Amula Sathishkumar5; S.G. Raman6; Janardhinakani Murugesan6; Baswant Mallipatil5; Krishnaprasad Bhat7; Krishna Reddy8; Channappa N. Patil9; Karthik Uduppa10

1Meenakshi Mission Hospital & Research Centre, Madurai, 2GVN Institute of Oncology, Trichy, 3Vydehi Institute of Medical Sciences, Begaluru, 4AlIMS, Nagpur, 5Columbia Asia Hospital, Begaluru, 6Madras Cancer Care Foundation, Chennai, 7Mangalore Institute of Oncology, Mangalore, 8Manipal Hospital, Vijayawada, 9Apollo Hospital, Bengaluru, 10Manipal Hospital, Manipal, India

10

INTERIM PET SCAN AFTER TWO CYCLES OF ABVD CHEMOTHERAPY IS THE STRONGEST PREDICTOR OF OUTCOME IN HODGKIN LYMPHOMA: REAL WORLD SCENARIO

Krishnakumar Rathnam1; Arun Seshachalam2; Shashidhar Karpurmath3; Krishna Reddy Golmari4; Ganapahti Raman5; Patil Chenappal6; Neelesh Reddy7; Krishnaprasad Bhat8; Bharat Rangarajan9; Karthik Udupa10; Manjunath Nandennavar3; Janardhina Kani5; Prasad Gunari11

1Meenakshi Mission Hospital & Research Centre, Madurai, 2GVN Institute of Oncology, Trichy, 3Vydehi Institute of Medical Sciences, Begaluru, 4Manipal Hospital, Vijayawada, 5Madras Cancer Care Foundation, Chennai, 6Apollo Hospital, Bengaluru, 7Columbia Asia Jospital, Begaluru, 8Mangalore Institute of Oncology, Mangalore, 9Kovai Medical Centre, Coimbatore, 10Manipal Hospital, Manipal, 11HCG Cancer Centre, Hubli, India

11

ADAMTS 13 LEVELS AND VON WILLEBRAND FACTOR (VWF) COLLAGEN ACTIVITY IN DENGUE FEVER (AVID STUDY)

Jayastu Senapati1; Sowmya Satheyndra2

1Department of Clinical Haematology and 2Department of Medicine, Christian Medical College and Hospital, Vellore, India

12

EVALUATION OF CHRONIC MIELOID LEUKEMIA DISTRIBUTION, DIAGNOSTICS AND TREATMENT IN AZERBAIJAN

Ayten Shirinova; Aypara Hasanova; Chingiz Asadov; Zohra Alimirzoyeva

Institute of Hematology and Transfuziology, Baku, Azerbaijan